MedPlus Health Services Subsidiary Faces Drug License Suspension in Maharashtra

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, has received a suspension order for a drug license of a store located in Maharashtra.

Regulatory Action Details

The suspension order was issued by the Assistant Commissioner Licensing Authority, Food Drug Administrations, Ahmednagar, Maharashtra. The order affects a store situated at Bhandari Colony, Ahmednagar, Maharashtra, and imposes a ten-day suspension of the drug license.

Parameter	Details
Authority	Asst. Commissioner Licensing Authority, Food Drug Administrations, Ahmednagar
Action Taken	Suspension of Drug License for ten days
Store Location	Bhandari Colony, Ahmednagar, Maharashtra
Legal Provision	Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of ₹2.00 lakhs due to the ten-day suspension of the drug license for the affected store.

Compliance Disclosure

This disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has informed both BSE Limited and National Stock Exchange of India Limited about this regulatory development as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Detailed information regarding this matter will be available on the company's website at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.07%	+1.76%	+3.70%	-4.58%	+2.32%	-25.59%

Medplus Health Services Limited has announced the release of pledged shares by its promoter entity Agilemed Investments Private Limited following successful debt repayment. The company filed the regulatory disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 31, marking the completion of its debt refinancing initiative.

Share Pledge Release Details

Agilemed Investments Private Limited released 41,71,970 equity shares from pledge arrangements on December 24. The release was executed following repayment of existing debt obligations to multiple lenders including Catalyst Trusteeship Limited and Modulus Alternatives Investment Managers Limited.

Parameter:	Details
Shares Released:	41,71,970 equity shares
Releasing Entity:	Agilemed Investments Private Limited
Release Date:	December 24, 2025
Reporting Date:	December 31, 2025
Share Value:	₹342.23 crores
Price per Share:	₹820.30

Updated Promoter Shareholding Structure

Following the pledge release, the promoter group's encumbrance profile has been significantly reduced. The total promoter shareholding remains stable at 40.29% while the pledged portion has decreased substantially.

Promoter Entity:	Total Holding	Pledged Shares	% of Total Capital
Agilemed Investments Pvt Ltd:	1,56,49,495 shares	1,14,77,525 shares	9.58%
Lone Furrow Investment Pvt Ltd:	25,00,000 shares	25,00,000 shares	2.09%
Madhukar Reddy Gangadi:	1,53,50,400 shares	1,53,50,400 shares	12.81%
Total Promoter Group:	4,82,80,627 shares	2,93,27,925 shares	24.48%

Debt Refinancing Framework

The share pledge release represents the successful completion of the debt refinancing framework involving non-convertible debentures. The arrangement included multiple financial instruments with structured repayment mechanisms to debenture trustees and lenders.

Financial Aspect:	Details
Debt Instrument:	Non-Convertible Debentures
Debenture Trustee:	Catalyst Trusteeship Limited
Primary Lender:	Modulus Alternatives Investment Managers Limited
Refinancing Amount:	₹321.00 crores
Security Cover Ratio:	2.00x

Regulatory Compliance and Impact

The company has fulfilled all disclosure requirements under SEBI regulations with comprehensive documentation filed on December 31, 2025. The encumbrance release demonstrates improved financial flexibility at the promoter level while maintaining strategic control over the healthcare retail chain.

The successful debt repayment and consequent pledge release reflects the company's strengthened financial position. This development provides enhanced operational flexibility to the promoter group while reducing overall leverage in the shareholding structure of Medplus Health Services Limited.